DL-Phenylalanine | DLPA BENEFITS


    • Supports mood
    • Supports nociceptive functions
    • Supports neurotransmitter synthesis


As the name suggests, DL-phenylalanine (DLPA) is a mix of the essential amino acid phenylalanine, which occurs naturally as L-phenylalanine and artificially as synthetic D-phenylalanine.


It is a stereoisomer, which means they have the same chemical formula and have a similar structure; the only difference is in the orientation of the atoms.


We are able to take advantage of both forms of antioxidants when DLPA is absorbed by our bodies.


Dopamine, noradrenaline, and adrenaline are synthesized from L-phenylalanine via L-tyrosine.

In addition to dopamine synthesis, L-phenylalanine also contributes to the production of phenylethylamine, a neurotransmitter and a neuromodulator popularly called “love drug.”


L-phenylalanine supports mood via dopamine and phenylethylamine production [1,2]. Molecular mechanisms and enzymes involved in the processing of information used to sense and avoid potentially tissue-damaging stimuli may be influenced by D-phenylalanine [3].


Brain function


  • [L-phenylalanine]
  • Precursor (via L-tyrosine) for dopamine, noradrenaline and adrenaline synthesis [1]
  • Precursor for phenylethylamine synthesis [2]
  • Modulates acetylcholinesterase activity [5–7]
  • Modulates brain ATPase activity [5,7]
  • Modulates glutamatergic neurotransmission [8]


Nociceptive functions


  • Supports neural encoding of sensory information [9–13]
  • Influences Enkephalinase activity [D-phenylalanine] [3,14,15]




  • Supports positive affect [4,16–18]
  • Supports mood stability [4]


Morning Momentum

Get Instant Access To A Simple, Proven System That Has Helped


IGNITE Their Health and Energy

to Create The Life They Deserve!

Learn More


[1]J.D. Fernstrom, M.H. Fernstrom, J. Nutr. 137 (2007) 1539S–1547S; discussion 1548S.
[2]M.D. Berry, J. Neurochem. 90 (2004) 257–271.
[3]L.M. Halpern, W.K. Dong, Pain 24 (1986) 223–237.
[4]D.R. Wood, F.W. Reimherr, P.H. Wender, Psychiatry Res. 16 (1985) 21–26.
[5]S. Tsakiris, Z. Naturforsch. C 56 (2001) 132–137.
[6]S. Tsakiris, P. Angelogianni, K.H. Schulpis, J.C. Stavridis, Clin. Biochem. 33 (2000) 103–106.
[7]S. Tsakiris, P. Kouniniotou-Krontiri, K.H. Schulpis, J.C. Stavridis, Z. Naturforsch. C 53 (1998) 163–167.
[8]A.V. Glushakov, D.M. Dennis, C. Sumners, C.N. Seubert, A.E. Martynyuk, J. Neurosci. Res. 72 (2003) 116–124.
[9]N.E. Walsh, S. Ramamurthy, L. Schoenfeld, J. Hoffman, Arch. Phys. Med. Rehabil. 67 (1986) 436–439.
[10]T. Nurmikko, A. Pertovaara, P.J. Pöntinen, Acupunct. Electrother. Res. 12 (1987) 185–191.
[11]T. Kitade, Y. Odahara, S. Shinohara, T. Ikeuchi, T. Sakai, K. Morikawa, M. Minamikawa, S. Toyota, A. Kawachi, M. Hyodo, Acupunct. Electrother. Res. 13 (1988) 87–97.
[12]T. Kitade, Y. Odahara, S. Shinohara, T. Ikeuchi, T. Sakai, K. Morikawa, M. Minamikawa, S. Toyota, A. Kawachi, M. Hyodo, Acupunct. Electrother. Res. 15 (1990) 121–135.
[13]A.L. Russell, M.F. McCarty, Med. Hypotheses 55 (2000) 283–288.
[14]S. Ehrenpreis, Acupunct. Electrother. Res. 7 (1982) 157–172.
[15]S. Ehrenpreis, Acupunct. Electrother. Res. 10 (1985) 203–208.
[16]H. Beckmann, D. Athen, M. Olteanu, R. Zimmer, Arch. Psychiatr. Nervenkr. 227 (1979) 49–58.
[17]H. Beckmann, M.A. Strauss, E. Ludolph, J. Neural Transm. 41 (1977) 123–134.
[18]E. Fischer, B. Heller, M. Nachon, H. Spatz, Arzneimittelforschung 25 (1975) 132.